The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
6-Aminonicotinamide promotes the reaction [IL6 protein results in increased expression of MT1 protein]; 6-Aminonicotinamide promotes the reaction [IL6 protein results in increased expression of MT2 protein]; IL6 protein promotes the reaction [6-Aminonicotinamide results in increased expression of FGF2 protein]; IL6 protein promotes the reaction [6-Aminonicotinamide results in increased expression of IL1B protein]; IL6 protein promotes the reaction [6-Aminonicotinamide results in increased expression of NTF3 protein]; IL6 protein promotes the reaction [6-Aminonicotinamide results in increased expression of TGFB1 protein]; IL6 protein promotes the reaction [6-Aminonicotinamide results in increased expression of TNF protein] 6-Aminonicotinamide results in increased expression of IL6 protein
6-Aminonicotinamide results in increased expression of MT1 protein MT1 protein results in decreased susceptibility to 6-Aminonicotinamide 6-Aminonicotinamide promotes the reaction [IL6 protein results in increased expression of MT1 protein]
6-Aminonicotinamide promotes the reaction [IL6 protein results in increased expression of MT2 protein] 6-Aminonicotinamide results in increased expression of MT2 protein MT2 protein results in decreased susceptibility to 6-Aminonicotinamide
6-Aminonicotinamide results in increased expression of NTF3 protein IL6 protein promotes the reaction [6-Aminonicotinamide results in increased expression of NTF3 protein]
6-Aminonicotinamide results in increased expression of TNF protein IL6 protein promotes the reaction [6-Aminonicotinamide results in increased expression of TNF protein]
[Lipopolysaccharides co-treated with Isoniazid] results in decreased expression of ABCB11 mRNA; obeticholic acid inhibits the reaction [Isoniazid results in decreased expression of ABCB11 mRNA] Isoniazid results in decreased expression of ABCB11 protein [Rifampin co-treated with Isoniazid] results in decreased expression of ABCB11 protein [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCB11 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCC2 protein; [Lipopolysaccharides co-treated with Isoniazid] results in decreased expression of ABCC2 mRNA Isoniazid results in decreased expression of ABCC2 mRNA
[Lipopolysaccharides co-treated with Isoniazid] results in increased expression of ABCC3 mRNA; obeticholic acid inhibits the reaction [Isoniazid results in decreased expression of ABCC3 mRNA]
Isoniazid results in increased expression of AGPAT3 mRNA [Zidovudine co-treated with Isoniazid] results in increased expression of AGPAT3 mRNA; silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in increased expression of AGPAT3 mRNA]
[Zidovudine co-treated with Isoniazid] results in decreased expression of APOA5 mRNA; silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of APOA5 mRNA] Isoniazid results in decreased expression of APOA5 mRNA
Isoniazid results in increased activity of ASL protein [Isoniazid co-treated with Zidovudine] results in increased activity of ASL protein; Silybin inhibits the reaction [[Isoniazid co-treated with Zidovudine] results in increased activity of ASL protein]
[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein] Isoniazid affects the expression of BAX protein Isoniazid results in increased expression of BAX mRNA Isoniazid results in increased expression of BAX protein chrysin inhibits the reaction [Isoniazid results in increased expression of BAX protein] Quercetin inhibits the reaction [Isoniazid results in increased expression of BAX protein]
[Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein] Isoniazid results in decreased expression of BCL2 mRNA Isoniazid results in decreased expression of BCL2 protein Quercetin inhibits the reaction [Isoniazid results in decreased expression of BCL2 protein]
[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein] Isoniazid results in increased activity of CASP3 protein [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CASP3 Isoniazid results in increased expression of CASP3 mRNA Isoniazid results in increased cleavage of CASP3 protein acadesine promotes the reaction [Isoniazid results in increased cleavage of CASP3 protein]; Quercetin inhibits the reaction [Isoniazid results in increased cleavage of CASP3 protein]
Isoniazid results in increased cleavage of CASP9 protein Isoniazid results in increased activity of CASP9 protein Quercetin inhibits the reaction [Isoniazid results in increased cleavage of CASP9 protein]
Isoniazid results in decreased activity of CAT protein [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CAT protein; chrysin inhibits the reaction [Isoniazid results in decreased activity of CAT protein]
[Zidovudine co-treated with Isoniazid] results in decreased expression of CYB5A mRNA; silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of CYB5A mRNA] Isoniazid results in decreased expression of CYB5A mRNA
[Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 mRNA; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 protein; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 mRNA]; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 protein]
CYP2E1 gene polymorphism affects the susceptibility to Isoniazid; CYP2E1 gene SNP affects the susceptibility to Isoniazid CYP2E1 protein results in increased susceptibility to Isoniazid GSTM1 protein inhibits the reaction [CYP2E1 protein results in increased susceptibility to Isoniazid] Isoniazid results in increased activity of CYP2E1 protein [Isoniazid co-treated with Rifampin co-treated with dendrobine] results in decreased expression of CYP2E1 mRNA; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP2E1 mRNA; Berberine inhibits the reaction [Isoniazid results in increased expression of CYP2E1 mRNA] Isoniazid results in increased expression of CYP2E1; Isoniazid results in increased expression of CYP2E1 mRNA; Isoniazid results in increased expression of CYP2E1 protein 2-(allylthio)pyrazine inhibits the reaction [Isoniazid results in increased expression of CYP2E1 protein]; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA; [Isoniazid results in increased activity of CYP2E1 protein] which results in increased metabolism of 4-dichlorobenzene; [Isoniazid results in increased expression of CYP2E1] which results in increased metabolism of Acetaminophen; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; diphenyleneiodonium inhibits the reaction [Isoniazid results in increased activity of CYP2E1 protein]; Isoniazid inhibits the reaction [CYP2E1 protein results in increased reduction of tirapazamine]; Isoniazid results in increased expression of and results in increased activity of CYP2E1 protein; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Rifampin inhibits the reaction [Isoniazid results in increased expression of CYP2E1 protein]; Thiram inhibits the reaction [Isoniazid results in increased activity of CYP2E1 protein]; Tiopronin inhibits the reaction [Isoniazid results in increased activity of CYP2E1 protein] CYP2E1 protein results in increased metabolism of Isoniazid
[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; [SOD2 co-treated with CYP3A4] affects the susceptibility to Isoniazid; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA] Isoniazid results in decreased activity of CYP3A4 protein CYP3A4 protein results in increased susceptibility to Isoniazid
Isoniazid results in increased expression of CYP3A23-3A1 mRNA Isoniazid results in increased activity of CYP3A23-3A1 protein diphenyleneiodonium inhibits the reaction [Isoniazid results in increased activity of CYP3A23-3A1 protein]
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CYP7A1 protein; [Lipopolysaccharides co-treated with Isoniazid] results in increased expression of CYP7A1 mRNA; obeticholic acid inhibits the reaction [Isoniazid results in increased expression of CYP7A1 mRNA] [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CYP7A1 protein; [Isoniazid co-treated with Vitamin B 6] results in increased expression of CYP7A1 mRNA
EPX protein results in increased oxidation of Isoniazid [EPX protein results in increased oxidation of Isoniazid] which results in increased chemical synthesis of isonicotinyl-NAD
Isoniazid inhibits the reaction [2-tert-butylhydroquinone results in increased expression of GCLC mRNA] Isoniazid results in increased expression of GCLC mRNA chrysin inhibits the reaction [Isoniazid results in increased expression of GCLC mRNA] Isoniazid results in decreased expression of GCLC mRNA
Isoniazid results in decreased expression of GCLM mRNA Isoniazid results in increased expression of GCLM mRNA chrysin inhibits the reaction [Isoniazid results in increased expression of GCLM mRNA]
chrysin inhibits the reaction [Isoniazid results in increased expression of GFAP mRNA]; chrysin inhibits the reaction [Isoniazid results in increased expression of GFAP protein] Isoniazid results in increased expression of GFAP mRNA; Isoniazid results in increased expression of GFAP protein
Isoniazid results in increased activity of GPT protein [Isoniazid co-treated with Rifampin] results in increased expression of GPT protein; [Rifampin co-treated with Isoniazid] results in increased activity of GPT protein; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of GPT protein] Quercetin inhibits the reaction [Isoniazid results in increased expression of GPT protein] [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPT protein; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein; [Lipopolysaccharides co-treated with Isoniazid] results in increased activity of GPT protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]; Isoniazid promotes the reaction [Zidovudine results in increased activity of GPT protein]; Silybin inhibits the reaction [Isoniazid promotes the reaction [Zidovudine results in increased activity of GPT protein]]
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]
GSTM1 protein inhibits the reaction [CYP2E1 protein results in increased susceptibility to Isoniazid] GSTM1 protein results in decreased susceptibility to Isoniazid
GSTT1 gene polymorphism affects the susceptibility to [Isoniazid co-treated with Rifampin]; GSTT1 gene polymorphism results in increased susceptibility to [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide]
HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased abundance of Reactive Oxygen Species]; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]
Isoniazid inhibits the reaction [2-tert-butylhydroquinone results in increased expression of HMOX1 mRNA] Isoniazid results in increased expression of HMOX1 mRNA chrysin inhibits the reaction [Isoniazid results in increased expression of HMOX1 mRNA] Isoniazid results in decreased expression of HMOX1 mRNA
Isoniazid results in increased expression of IL6 protein Isoniazid results in increased expression of IL6 mRNA chrysin inhibits the reaction [Isoniazid results in increased expression of IL6 mRNA] Isoniazid results in increased secretion of IL6 protein
Isoniazid results in decreased phosphorylation of MAPK1 protein 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Quercetin inhibits the reaction [Isoniazid results in decreased phosphorylation of MAPK1 protein]]; Quercetin inhibits the reaction [Isoniazid results in decreased phosphorylation of MAPK1 protein]
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Quercetin inhibits the reaction [Isoniazid results in decreased phosphorylation of MAPK3 protein]]; Quercetin inhibits the reaction [Isoniazid results in decreased phosphorylation of MAPK3 protein]
[[MPO protein results in increased oxidation of Isoniazid] which results in increased chemical synthesis of Free Radicals] which results in increased chemical synthesis of isonicotinyl-NAD; [MPO protein results in increased oxidation of Isoniazid] which results in increased chemical synthesis of Free Radicals; [MPO protein results in increased oxidation of Isoniazid] which results in increased chemical synthesis of isonicotinyl-NAD
NAT2 protein polymorphism results in increased acetylation of Isoniazid; NAT2 protein results in increased acetylation of Isoniazid NAT2 protein polymorphism affects the acetylation of Isoniazid [Zidovudine co-treated with Isoniazid] results in decreased expression of NAT2 mRNA; silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of NAT2 mRNA] Isoniazid results in decreased expression of NAT2 mRNA [NAT2 gene polymorphism results in decreased acetylation of Isoniazid] which results in decreased abundance of acetylisoniazid; [NAT2 gene polymorphism results in decreased metabolism of Isoniazid] which results in increased abundance of hydrazine NAT2 protein results in increased metabolism of Isoniazid NAT2 protein affects the metabolism of Isoniazid; NAT2 protein polymorphism affects the metabolism of Isoniazid NAT2 gene polymorphism affects the susceptibility to Isoniazid; NAT2 gene SNP affects the susceptibility to Isoniazid
Isoniazid results in increased activity of NFE2L2 protein Isoniazid results in increased expression of NFE2L2 mRNA chrysin inhibits the reaction [Isoniazid results in increased expression of NFE2L2 mRNA]
Isoniazid inhibits the reaction [2-tert-butylhydroquinone results in increased expression of NQO1 mRNA] Isoniazid results in increased expression of NQO1 mRNA chrysin inhibits the reaction [Isoniazid results in increased expression of NQO1 mRNA] Isoniazid results in decreased expression of NQO1 mRNA
Isoniazid results in decreased expression of NR0B2 mRNA [Isoniazid co-treated with Vitamin B 6] results in decreased expression of NR0B2 mRNA obeticholic acid inhibits the reaction [Isoniazid results in decreased expression of NR0B2 mRNA]
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of NR1H4; [Lipopolysaccharides co-treated with Isoniazid] results in decreased expression of NR1H4 mRNA; [Lipopolysaccharides co-treated with Isoniazid] results in decreased expression of NR1H4 protein; obeticholic acid inhibits the reaction [Isoniazid results in decreased expression of NR1H4 mRNA] [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of NR1H4; [Isoniazid co-treated with Vitamin B 6] results in decreased expression of NR1H4 mRNA isoniazide decreases expression of nr1h4 protein in rat liver
[Zidovudine co-treated with Isoniazid] results in decreased expression of POR mRNA; silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of POR mRNA] Isoniazid results in decreased expression of POR mRNA
Isoniazid results in decreased expression of PPARG mRNA [Isoniazid co-treated with Rifampin] results in decreased expression of PPARG protein Isoniazid results in decreased expression of PPARG mRNA; Isoniazid results in decreased expression of PPARG protein
Isoniazid results in decreased expression of PPARGC1A protein acadesine inhibits the reaction [Isoniazid results in decreased expression of PPARGC1A protein]
acadesine inhibits the reaction [Isoniazid results in decreased expression of SIRT1 protein]; Quercetin inhibits the reaction [Isoniazid results in decreased expression of SIRT1 protein]
Isoniazid results in decreased expression of SLC10A1 mRNA Isoniazid results in decreased expression of SLC10A1 protein [Rifampin co-treated with Isoniazid] results in decreased expression of SLC10A1 protein [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of SLC10A1 obeticholic acid promotes the reaction [Isoniazid results in decreased expression of SLC10A1 mRNA]
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]
Isoniazid results in increased expression of TNF protein [Isoniazid co-treated with Zidovudine] results in increased expression of TNF protein; chrysin inhibits the reaction [Isoniazid results in increased expression of TNF protein]; Isoniazid promotes the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Silybin inhibits the reaction [[Isoniazid co-treated with Zidovudine] results in increased expression of TNF protein] Isoniazid results in increased secretion of TNF protein
IDH2 protein mutant form results in increased abundance of N-methylnicotinamide Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of N-methylnicotinamide]
nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Adenosine Triphosphate]; nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of NAD]
[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of 2,6-Dichloroindophenol; [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q1; [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2; [NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; chrysoeriol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]; Melatonin inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; Melatonin inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]; N-(2-(2-methoxy-6H-dipyrido(2,3-a-3,2-e)pyrrolizin-11-yl)ethyl)-2-furamide inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; N-(2-(2-methoxy-6H-dipyrido(2,3-a-3,2-e)pyrrolizin-11-yl)ethyl)-2-furamide inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3]; resveratrol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Ubiquinone Q2]; resveratrol inhibits the reaction [[NQO2 protein results in increased oxidation of nicotinamide-beta-riboside] which results in increased reduction of Vitamin K 3] NQO2 protein results in increased oxidation of nicotinamide-beta-riboside; NQO2 protein results in increased oxidation of nicotinamide-beta-riboside metabolite
Nicorandil inhibits the reaction [Doxorubicin results in increased expression of BAX protein] Nicorandil inhibits the reaction [Folic Acid results in increased expression of BAX protein]
[Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in decreased activity of CTSD protein]; [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of CTSD protein]
[Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in decreased activity of GAL protein]; [Nicorandil co-treated with Amlodipine] inhibits the reaction [Isoproterenol results in increased activity of GAL protein]
Nicorandil inhibits the reaction [Doxorubicin results in increased expression of IL1B protein]; Nicorandil inhibits the reaction [Methotrexate results in increased expression of IL1B protein]
Nicorandil inhibits the reaction [Folic Acid results in decreased expression of NOS3 protein] Nicorandil inhibits the reaction [Methotrexate results in decreased expression of NOS3 protein]
Nicorandil inhibits the reaction [Doxorubicin results in increased expression of TNF protein]; Nicorandil inhibits the reaction [Methotrexate results in increased expression of TNF protein] Nicorandil inhibits the reaction [Folic Acid results in increased expression of TNF protein]
Nicorandil inhibits the reaction [AGT protein modified form results in increased expression of XDH protein] Nicorandil results in decreased expression of XDH protein
Niacinamide inhibits the reaction [6,8-diallyl 5,7-dihydroxy 2-(2-allyl 3-hydroxy 4-methoxyphenyl)1-H benzo(b)pyran-4-one results in increased phosphorylation of ACACA protein] [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of ACACA mRNA] Niacinamide results in decreased phosphorylation of ACACA protein
2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of ACE mRNA]; [Streptozocin co-treated with Niacinamide] results in increased expression of ACE mRNA; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of ACE mRNA]
2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of ACE2 mRNA]; [Streptozocin co-treated with Niacinamide] results in decreased expression of ACE2 mRNA; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of ACE2 mRNA]
Niacinamide results in increased secretion of ADIPOQ protein [Alloxan co-treated with Niacinamide] affects the expression of ADIPOQ protein; [Streptozocin co-treated with Niacinamide] results in decreased expression of ADIPOQ protein; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of ADIPOQ protein]
Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of AGO2 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of AGO2 protein]
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [resveratrol results in decreased expression of AGTR1 mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of AGTR1 mRNA 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of AGTR1A mRNA]; [Streptozocin co-treated with Niacinamide] results in increased expression of AGTR1A mRNA; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of AGTR1A mRNA]
[Streptozocin co-treated with Niacinamide] results in decreased phosphorylation of AKT1 protein; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased phosphorylation of AKT1 protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased phosphorylation of AKT1 protein]
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of APAF1 protein]
Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of BAX protein] [Berberine co-treated with Niacinamide] results in increased expression of BAX protein [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of BAX protein] Niacinamide results in increased expression of BAX mRNA; Niacinamide results in increased expression of BAX protein
[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 protein] [Berberine co-treated with Niacinamide] results in decreased expression of BCL2 protein; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of BCL2 protein]
[Berberine co-treated with Niacinamide] results in increased expression of BCL2L11 mRNA; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased expression of BCL2L11 protein] Niacinamide results in increased expression of BCL2L11 mRNA
Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BMI1 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BMI1 protein]
Niacinamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein] Niacinamide results in increased cleavage of CASP3 protein [Berberine co-treated with Niacinamide] results in increased cleavage of CASP3 protein; resveratrol inhibits the reaction [Niacinamide results in increased cleavage of CASP3 protein] [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP3 protein]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP3 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP3 protein]; Niacinamide promotes the reaction [Antimycin A results in increased cleavage of CASP3 protein]; Niacinamide promotes the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]
Niacinamide inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP9 protein] [Berberine co-treated with Niacinamide] results in increased cleavage of CASP9 protein [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP9 protein]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased activity of CASP9 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CASP9 protein]
[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein; [Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein; [Streptozocin co-treated with Niacinamide] results in decreased expression of CAT protein; coumarin inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; Diosmin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of CAT protein]; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Pioglitazone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of CAT protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of CAT protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; Saponins inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; thymoquinone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein] 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]; [Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of CAT protein]
CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]
Niacinamide inhibits the reaction [tert-Butylhydroperoxide results in increased expression of CDKN1A protein] Niacinamide results in increased expression of CDKN1A protein Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1A protein]] [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A mRNA]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A protein] Niacinamide results in decreased expression of CDKN1A protein
Niacinamide results in increased expression of CDKN1B protein Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]
Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN2A protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of CDKN2A promoter]
Niacinamide results in increased activity of CHUK protein resveratrol inhibits the reaction [Niacinamide results in increased activity of CHUK protein]
Niacinamide results in decreased expression of COL1A1 mRNA Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA]]
Clofibrate inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA]; GW 6471 inhibits the reaction [Resveratrol inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA]]; Resveratrol inhibits the reaction [Niacinamide results in increased expression of CYBA mRNA]
2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NOX2 mRNA]; [Streptozocin co-treated with Niacinamide] results in increased expression of NOX2 mRNA; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NOX2 mRNA]
[Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]
[Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]
Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DICER1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DICER1 protein]
[Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DLG1 mRNA; Niacinamide inhibits the reaction [geranylgeranylacetone results in increased expression of DLG1 mRNA]
Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNMT1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of DNMT1 protein]
Niacinamide results in increased phosphorylation of EIF4EBP1 protein [Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of EIF4EBP1 protein; Niacinamide inhibits the reaction [Resveratrol results in decreased phosphorylation of EIF4EBP1 protein]
ERCC6 gene mutant form results in increased abundance of Niacinamide ERCC6 gene mutant form promotes the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in decreased abundance of Niacinamide]
CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]; Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]
Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of G6PC1 mRNA]; Niacinamide inhibits the reaction [FOXO1 protein results in increased expression of IGFBP1 mRNA] [Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO1 protein; Niacinamide results in increased expression of and results in increased acetylation of FOXO1 protein Niacinamide inhibits the reaction [Dexamethasone results in decreased acetylation of FOXO1 protein]; Niacinamide inhibits the reaction [FOXO1 protein binds to SIRT1 protein]
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO3 protein; Niacinamide inhibits the reaction [icariin inhibits the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased acetylation of and results in increased expression of FOXO3 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of FOXO3 protein]; Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in increased acetylation of FOXO3 protein]; Niacinamide results in increased expression of and results in increased acetylation of FOXO3 protein
[Streptozocin co-treated with Niacinamide] affects the activity of G6PD protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of G6PD protein]
[Streptozocin co-treated with Niacinamide] results in decreased expression of GCG mRNA; Sitagliptin Phosphate inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCG mRNA]
[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA; [Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GCLC protein]
Niacinamide inhibits the reaction [Sirolimus inhibits the reaction [Glucose results in increased expression of GLB1 protein]] Niacinamide results in increased expression of GLB1 protein
[Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GLO1 protein]
[Resveratrol co-treated with Niacinamide] inhibits the reaction [[Aflatoxin B1 co-treated with Ethanol] results in increased expression of GPT protein]
[Niacinamide co-treated with Resveratrol] inhibits the reaction [[Ethanol co-treated with Aflatoxin B1] results in decreased expression of GSR protein]; [Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein; [Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased activity of GSR protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of GSR protein]
[Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of GSTM3 mRNA]
[Niacinamide co-treated with Resveratrol] inhibits the reaction [[Ethanol co-treated with Aflatoxin B1] results in increased expression of GSTP1 protein]
[Streptozocin co-treated with Niacinamide] affects the activity of GYS2 protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of GYS2 protein]
[Streptozocin co-treated with Niacinamide] results in increased glycosylation of HBA1 protein; coumarin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased glycosylation of HBA1 protein]
Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of HDAC1 mRNA]; Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of HDAC1 protein]
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of HMGCR mRNA]; [Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in increased activity of HMGCR protein] Nicotinamide decreases expression of Hmgcr protein in kidney of 5/6 nephrectomized rats
[Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of HMOX1 protein]
2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 mRNA]; 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 protein]; [Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 mRNA; [Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 mRNA]; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IL10 protein]
[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein; [Streptozocin co-treated with Niacinamide co-treated with ENV-2 compound] results in decreased expression of IL1B mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL1B protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL1B protein] Niacinamide results in decreased expression of IL1B mRNA Niacinamide results in increased expression of IL1B mRNA
Niacinamide results in decreased expression of IL6 protein [Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein; [Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein]; resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of IL6 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of IL6 protein]
[Niacinamide co-treated with Streptozocin] results in decreased expression of INS1 protein; [Streptozocin co-treated with Niacinamide] results in decreased expression of INS1 protein; [Streptozocin co-treated with Niacinamide] results in decreased secretion of INS1 protein; [Streptozocin co-treated with Niacinamide] results in increased expression of INS1 protein; coumarin inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in decreased expression of INS1 protein]; coumarin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of INS1 protein]; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of INS1 protein]; Niacinamide inhibits the reaction [Glucose results in increased expression of INS1 protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of INS1 protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of INS1 protein]; thymoquinone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of INS1 protein]; thymoquinone inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased secretion of INS1 protein]
Niacinamide inhibits the reaction [Glucose inhibits the reaction [MAFA protein binds to INS promoter]]; Niacinamide inhibits the reaction [Glucose results in increased expression of INS mRNA]; Niacinamide inhibits the reaction [Glucose results in increased expression of INS protein]
[Streptozocin co-treated with Niacinamide] results in decreased expression of INSR protein; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of INSR protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of INSR protein]
[Streptozocin co-treated with Niacinamide] results in decreased expression of IRS2 protein; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IRS2 protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of IRS2 protein]
Niacinamide inhibits the reaction [Methylnitrosourea results in increased expression of JUN protein]; Niacinamide inhibits the reaction [Methylnitrosourea results in increased phosphorylation of JUN protein]
[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of KEAP1 protein] 2,5-dihydroxybenzoic acid promotes the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of KEAP1 mRNA]; [Streptozocin co-treated with Niacinamide] results in decreased expression of KEAP1 mRNA; Metformin promotes the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of KEAP1 mRNA]; Niacinamide inhibits the reaction [Acetaminophen results in increased expression of KEAP1 protein]
[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LCAT protein]
[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein; [tetrahydrocurcumin co-treated with Chlorogenic Acid] results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein]; Chlorogenic Acid results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein]; tetrahydrocurcumin results in decreased susceptibility to [[Streptozocin co-treated with Niacinamide] results in decreased activity of LPL protein]
2,5-dihydroxybenzoic acid promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of MIR200A]; [Streptozocin co-treated with Niacinamide] results in increased expression of MIR200A; Metformin promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of MIR200A]
Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene affects the expression of MIR203 mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased methylation of MIR203 promoter]
Niacinamide results in increased expression of MMP9 protein Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of MMP9 protein]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of MMP9 protein]
Niacinamide results in increased phosphorylation of MTOR protein Niacinamide inhibits the reaction [resveratrol results in decreased phosphorylation of MTOR protein]
Niacinamide affects the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC mRNA]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of MYC protein]; Niacinamide inhibits the reaction [Butylhydroxybutylnitrosamine results in increased expression of and results in increased localization of MYC protein]
Niacinamide results in decreased ubiquitination of NABP2 protein Niacinamide results in increased acetylation of NABP2 protein Niacinamide promotes the reaction [trichostatin A results in decreased ubiquitination of NABP2 protein]; Niacinamide promotes the reaction [trichostatin A results in increased acetylation of NABP2 protein]; trichostatin A promotes the reaction [Niacinamide results in decreased ubiquitination of NABP2 protein]; trichostatin A promotes the reaction [Niacinamide results in increased acetylation of NABP2 protein]
Niacinamide results in decreased expression of NAMPT protein Niacinamide inhibits the reaction [[Acetaminophen results in decreased expression of NAMPT protein] which results in decreased abundance of NAD]; Niacinamide inhibits the reaction [Acetaminophen results in decreased expression of NAMPT protein] Niacinamide inhibits the reaction [Letrozole results in increased expression of NAMPT mRNA] [Berberine co-treated with Niacinamide] results in decreased expression of NAMPT protein
Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA13 mRNA]; Niacinamide inhibits the reaction [resveratrol results in increased expression of NDUFA13 protein]
[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA; [Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 mRNA]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of NFE2L2 protein] 2,5-dihydroxybenzoic acid promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NFE2L2 protein]; [Niacinamide co-treated with Acetaminophen] affects the localization of NFE2L2 protein; [Streptozocin co-treated with Niacinamide] results in increased expression of NFE2L2 protein; Metformin promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NFE2L2 protein]; Niacinamide inhibits the reaction [Acetaminophen results in decreased expression of NFE2L2 protein]
Niacinamide inhibits the reaction [resveratrol results in decreased expression of NOS2 mRNA]; Niacinamide inhibits the reaction [resveratrol results in decreased expression of NOS2 protein]
GW 6471 inhibits the reaction [resveratrol inhibits the reaction [Niacinamide results in increased expression of NOX4 mRNA]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of NOX4 mRNA]
2,5-dihydroxybenzoic acid promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NQO1 mRNA]; [Streptozocin co-treated with Niacinamide] results in increased expression of NQO1 mRNA; Metformin promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of NQO1 mRNA]
[Glycerol co-treated with Succinic Acid co-treated with Glucose-6-Phosphate co-treated with Pantothenic Acid co-treated with Niacinamide] results in increased expression of NR4A1 mRNA
Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in decreased expression of PARP1 protein]; Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in increased activity of PARP1 protein]; Niacinamide inhibits the reaction [Methylnitrosourea results in increased activity of PARP1 protein] Niacinamide results in increased expression of PARP1 mRNA; Niacinamide results in increased expression of PARP1 protein [Berberine co-treated with Niacinamide] results in increased cleavage of PARP1 protein; Niacinamide inhibits the reaction [sodium arsenite results in decreased expression of PARP1 protein] Niacinamide results in increased cleavage of PARP1 protein Niacinamide results in decreased activity of PARP1 protein
Niacinamide inhibits the reaction [Butylhydroxybutylnitrosamine results in decreased expression of and results in decreased localization of PMP22 protein]
Niacinamide affects the reaction [PPARG protein binds to NCOR1 protein]; resveratrol inhibits the reaction [Niacinamide results in increased expression of PPARG protein] [Streptozocin co-treated with Niacinamide] results in decreased expression of PPARG protein; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of PPARG protein]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of PPARG protein]
Niacinamide results in increased acetylation of PPARGC1A protein [Niacinamide results in decreased activity of SIRT1 protein] which results in increased acetylation of PPARGC1A protein [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [SIRT1 protein results in increased expression of PPARGC1A mRNA]
Niacinamide results in increased expression of PTGS2 protein Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]]; resveratrol inhibits the reaction [Niacinamide results in increased expression of PTGS2 protein]
[Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] affects the activity of PYGL protein]
[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein; [Streptozocin co-treated with Niacinamide] results in increased activity of RELA protein; [Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein]; Gliclazide inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein]; Niacinamide inhibits the reaction [AICA ribonucleotide inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [Metformin inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; Niacinamide inhibits the reaction [Salicylic Acid inhibits the reaction [Palmitic Acid results in increased phosphorylation of RELA protein]]; resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of RELA protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased activity of RELA protein]; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of RELA protein] Niacinamide results in increased acetylation of and results in increased phosphorylation of RELA protein; resveratrol inhibits the reaction [Niacinamide results in increased phosphorylation of and results in increased acetylation of RELA protein] 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased phosphorylation of RELA protein]; [Streptozocin co-treated with Niacinamide] results in increased phosphorylation of RELA protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased phosphorylation of RELA protein]; Niacinamide inhibits the reaction [Resveratrol results in decreased expression of RELA protein modified form]; Niacinamide promotes the reaction [TNF protein results in increased acetylation of RELA protein]
Niacinamide results in decreased expression of RUNX2 mRNA; Niacinamide results in decreased expression of RUNX2 protein resveratrol inhibits the reaction [Niacinamide results in decreased expression of RUNX2 protein] Niacinamide results in increased expression of RUNX2 mRNA
Niacinamide promotes the reaction [[Oxygen deficiency co-treated with Oxygen] results in increased expression of SHC1 protein] Niacinamide results in increased expression of SHC1 mRNA; Niacinamide results in increased expression of SHC1 protein
[Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [SIRT1 protein results in increased expression of PPARGC1A mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DLG1 mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to resveratrol; Niacinamide inhibits the reaction [[SIRT1 protein binds to UCP2 promoter] which results in decreased expression of UCP2 mRNA] Niacinamide results in decreased expression of SIRT1 mRNA; Niacinamide results in decreased expression of SIRT1 protein [Niacinamide co-treated with Resveratrol] promotes the reaction [[Ethanol co-treated with Aflatoxin B1] results in increased expression of SIRT1 mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Cholesterol]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased abundance of Glucose]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of ACACA mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Fructose results in increased expression of HMGCR mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] inhibits the reaction [Resveratrol results in decreased expression of AGTR1 mRNA]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to AICA ribonucleotide; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Fructose; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Metformin; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Resveratrol; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased susceptibility to Salicylic Acid; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased acetylation of PPARGC1A protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of AGTR1 mRNA; [Resveratrol co-treated with Niacinamide] promotes the reaction [[Ethanol co-treated with Aflatoxin B1] results in increased expression of SIRT1 protein]; Niacinamide inhibits the reaction [Excitatory Amino Acid Agonists results in decreased expression of and results in decreased activity of SIRT1 protein]; Niacinamide inhibits the reaction [FOXO1 protein binds to SIRT1 protein]; Niacinamide inhibits the reaction [Resveratrol promotes the reaction [Pilocarpine results in increased expression of SIRT1 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 mRNA]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 protein]; Niacinamide inhibits the reaction [SIRT1 protein results in decreased abundance of NAD] [Berberine co-treated with Niacinamide] results in decreased expression of SIRT1 protein; [Niacinamide results in decreased activity of SIRT1 protein] promotes the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein]; [Niacinamide results in decreased activity of SIRT1 protein] which results in decreased expression of DEFB4A mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased expression of CXCL8 mRNA; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of EIF4EBP1 protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased phosphorylation of RPS6 protein; [Niacinamide results in decreased activity of SIRT1 protein] which results in increased susceptibility to Hydrogen Peroxide; Niacinamide inhibits the reaction [1,5-dihydroxyisoquinoline inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased activity of SIRT1 protein]]; Niacinamide inhibits the reaction [icariin inhibits the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of SIRT1 protein]]; Niacinamide inhibits the reaction [Resveratrol results in increased expression of SIRT1 protein]; Niacinamide inhibits the reaction [salvin inhibits the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of SIRT1 protein]]; Niacinamide promotes the reaction [[Oxygen deficiency co-treated with Oxygen] results in decreased expression of SIRT1 protein]; Niacinamide results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein]
[Streptozocin co-treated with Niacinamide] results in decreased expression of SLC2A4 protein; eupafolin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of SLC2A4 protein]; Niacinamide inhibits the reaction [Letrozole results in decreased expression of SLC2A4 mRNA]; Quercetin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of SLC2A4 protein]
[Streptozocin co-treated with Niacinamide] results in decreased expression of SNAP23 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of SNAP23 mRNA]
[Streptozocin co-treated with Niacinamide] results in increased expression of SOD1 protein; Dronabinol promotes the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of SOD1 protein] 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of SOD1 protein]; [Streptozocin co-treated with Niacinamide] results in decreased activity of SOD1 protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased activity of SOD1 protein]
Niacinamide inhibits the reaction [resveratrol results in increased expression of SOD2 mRNA] Niacinamide promotes the reaction [[Oxygen co-treated with Oxygen deficiency] results in decreased expression of SOD2 protein]
Niacinamide results in decreased expression of SOX9 protein 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline inhibits the reaction [Niacinamide results in decreased expression of SOX9 protein]; resveratrol inhibits the reaction [Niacinamide results in decreased expression of SOX9 protein]
[Streptozocin co-treated with Niacinamide] results in decreased expression of STX4 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of STX4 mRNA]
2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 mRNA]; 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 protein]; [Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 mRNA]; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TGFB1 protein] Niacinamide results in increased expression of TGFB1 mRNA; Niacinamide results in increased expression of TGFB1 protein
Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TGFB2 protein results in increased expression of COL1A2 mRNA]]
[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein; [Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein; Gliclazide inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein]; Resveratrol inhibits the reaction [[Niacinamide co-treated with Streptozocin] results in increased expression of TNF protein]; Resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein] Niacinamide inhibits the reaction [[TNF protein co-treated with resveratrol] results in increased expression of MAP1LC3B protein alternative form]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of MMP9 protein]]; Niacinamide inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]] 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF mRNA]; 2,5-dihydroxybenzoic acid inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein]; [Streptozocin co-treated with Niacinamide] results in increased expression of TNF mRNA; [Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF mRNA]; Metformin inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in increased expression of TNF protein]; Niacinamide promotes the reaction [TNF protein results in increased acetylation of RELA protein]; Niacinamide promotes the reaction [TNF protein results in increased expression of CD40 mRNA] Niacinamide results in increased expression of TNF mRNA
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of TP53 protein; [Niacinamide results in decreased activity of SIRT1 protein] promotes the reaction [Hydrogen Peroxide results in increased acetylation of TP53 protein]; Niacinamide inhibits the reaction [tert-Butylhydroperoxide results in increased expression of TP53 protein]; Niacinamide results in decreased activity of [SIRT1 protein results in decreased acetylation of TP53 protein]; Niacinamide results in increased phosphorylation of and results in increased acetylation of TP53 protein [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 mRNA alternative form]; [Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 protein]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 mRNA alternative form]; Niacinamide inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of TRP53 protein] Niacinamide results in decreased expression of TP53 protein
[Streptozocin co-treated with Niacinamide] results in decreased expression of VAMP2 mRNA; resveratrol inhibits the reaction [[Streptozocin co-treated with Niacinamide] results in decreased expression of VAMP2 mRNA]
[Chromium co-treated with Niacin] results in decreased expression of ABCA1 mRNA Niacin results in increased expression of ABCA1 mRNA Niacin results in decreased expression of ABCA1 protein 2-chloro-5-nitrobenzanilide inhibits the reaction [Niacin results in increased expression of ABCA1 mRNA]; [[Niacin binds to and results in increased activity of HCAR2 protein] which results in decreased expression of ABCA1 protein] which results in decreased export of Cholesterol; [Niacin binds to and results in increased activity of HCAR2 protein] which results in decreased expression of ABCA1 protein; ABCA1 protein promotes the reaction [Niacin results in increased export of Cholesterol, HDL]; PPARG protein promotes the reaction [Niacin results in increased expression of ABCA1 mRNA]
Niacin results in decreased expression of ABCG1 protein [Niacin results in increased expression of ABCG1 protein] which results in increased export of Cholesterol; ABCG1 protein promotes the reaction [Niacin results in increased export of Cholesterol, HDL]; HCAR2 protein inhibits the reaction [[Niacin results in increased expression of ABCG1 protein] which results in increased export of Cholesterol]
[Curcumin co-treated with Niacin co-treated with ZM 241385] inhibits the reaction [Rotenone results in increased expression of ACHE protein]; Niacin inhibits the reaction [Rotenone results in increased expression of ACHE protein]
ACMSD protein affects the abundance of Niacin ACMSD protein affects the metabolism of Niacin [ACMSD protein affects the metabolism of Niacin] which affects the abundance of N'-methyl-2-pyridone-5-carboxamide; [ACMSD protein affects the metabolism of Niacin] which affects the abundance of N(1)-methyl-4-pyridone-5-carboxamide [Diethylhexyl Phthalate results in decreased activity of ACMSD protein] which results in increased abundance of Niacin; Dibutyl Phthalate affects the reaction [ACMSD protein affects the abundance of Niacin]
Niacin results in increased expression of ADIPOQ mRNA; Niacin results in increased expression of ADIPOQ protein HCAR2 protein promotes the reaction [Niacin results in increased expression of ADIPOQ protein] Niacin promotes the reaction [ADIPOQ protein binds to ADIPOQ protein]
[Curcumin co-treated with Niacin co-treated with ZM 241385] inhibits the reaction [Rotenone results in increased expression of ADORA2A mRNA]; Niacin inhibits the reaction [Rotenone results in increased expression of ADORA2A mRNA]
Niacin inhibits the reaction [AGT protein results in increased abundance of Reactive Oxygen Species] [Curcumin co-treated with Niacin co-treated with ZM 241385] inhibits the reaction [Rotenone results in increased expression of AGT protein]; Niacin inhibits the reaction [Rotenone results in increased expression of AGT protein] Niacin results in decreased expression of AGT protein
[Chromium co-treated with Niacin] results in increased expression of APOA1 mRNA; [Lovastatin co-treated with Niacin] results in increased expression of APOA1 protein; [Niacin co-treated with Ezetimibe co-treated with Simvastatin] results in increased expression of APOA1 protein; [Niacin co-treated with Lovastatin] results in increased expression of APOA1 protein; Niacin promotes the reaction [[Simvastatin co-treated with Ezetimibe] results in increased expression of APOA1 protein]; Niacin promotes the reaction [Rosuvastatin Calcium results in increased expression of APOA1 protein] 2-chloro-5-nitrobenzanilide inhibits the reaction [Niacin promotes the reaction [APOA1 protein results in increased export of Cholesterol]]; Niacin promotes the reaction [APOA1 protein results in increased export of Cholesterol]; PPARG protein promotes the reaction [Niacin promotes the reaction [APOA1 protein results in increased export of Cholesterol]] Niacin results in increased expression of APOA1 protein
[Niacin co-treated with Lovastatin] results in decreased expression of APOB protein; [Niacin co-treated with Simvastatin] results in decreased expression of APOB protein Niacin results in decreased expression of APOB protein
[Curcumin co-treated with Niacin co-treated with ZM 241385] inhibits the reaction [Rotenone results in increased activity of CASP3 protein]; Niacin inhibits the reaction [Rotenone results in increased activity of CASP3 protein]
[Niacin co-treated with Chromium] inhibits the reaction [CAV1 protein binds to NOS3 protein]; [Niacin co-treated with Chromium] results in decreased expression of CAV1 protein
[Niacin co-treated with Chromium] promotes the reaction [SLC2A4 protein binds to CAV3 protein]; [Niacin co-treated with Chromium] results in increased expression of CAV3 protein
[Niacin inhibits the reaction [CEBPB protein binds to PTGS2 promoter]] which results in decreased expression of PTGS2 mRNA; Niacin inhibits the reaction [CEBPB protein binds to PTGS2 promoter] Niacin results in decreased expression of CEBPB mRNA; Niacin results in decreased expression of CEBPB protein
[Niacin results in decreased expression of and results in decreased activity of CERT1 protein] which results in increased abundance of Cholesterol, HDL; Niacin results in decreased expression of and results in decreased activity of CERT1 protein
[resveratrol co-treated with pterostilbene co-treated with Quercetin co-treated with tocotrienol, delta co-treated with Niacin] results in decreased expression of CRP protein; [Simvastatin co-treated with Ezetimibe] promotes the reaction [Niacin results in decreased expression of CRP protein] [Curcumin co-treated with Niacin co-treated with ZM 241385] inhibits the reaction [Rotenone results in increased expression of CRP protein]; Niacin inhibits the reaction [Rotenone results in increased expression of CRP protein]
[Niacin results in decreased abundance of Dinoprost] which results in increased expression of FABP4 mRNA; [Niacin results in decreased abundance of Dinoprost] which results in increased expression of FABP4 protein; fluprostenol inhibits the reaction [Niacin results in increased expression of FABP4 mRNA]
[Niacin results in decreased abundance of Fatty Acids, Nonesterified] which results in increased secretion of GCG protein; Glucose inhibits the reaction [[Niacin results in decreased abundance of Fatty Acids, Nonesterified] which results in increased secretion of GCG protein]
[Niacin results in decreased abundance of Fatty Acids, Nonesterified] which results in increased secretion of GH1 protein; Glucose inhibits the reaction [[Niacin results in decreased abundance of Fatty Acids, Nonesterified] which results in increased secretion of GH1 protein]
[Niacin binds to and results in increased activity of HCAR2 protein] which results in increased phosphorylation of MAPK1 protein; [Niacin binds to and results in increased activity of HCAR2 protein] which results in increased phosphorylation of MAPK3 protein; [Niacin results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; HCAR2 protein promotes the reaction [Niacin results in increased expression of and results in increased activity of PPARG protein]; Niacin binds to and affects the activity of HCAR2 protein; Niacin binds to and results in increased activity of HCAR2 protein [Niacin analog binds to and results in increased activity of HCAR2 protein] which results in decreased abundance of Fatty Acids, Nonesterified; [Niacin binds to and results in increased activity of HCAR2 protein] which results in decreased abundance of Fatty Acids, Nonesterified; Niacin binds to and results in increased activity of HCAR2 protein Niacin binds to HCAR2 protein
Niacin inhibits the reaction [IFNG protein results in increased expression of ICAM1 protein]; Niacin inhibits the reaction [IL1B protein results in increased expression of ICAM1 protein]; Niacin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA] [Niacin co-treated with Chromium] inhibits the reaction [Dietary Fats results in increased expression of ICAM1 mRNA]; [Niacin co-treated with Chromium] inhibits the reaction [Dietary Fats results in increased expression of ICAM1 protein] Niacin results in decreased expression of ICAM1 protein
[Ubiquinone co-treated with Niacin co-treated with Riboflavin] promotes the reaction [Tamoxifen results in decreased expression of IL1B protein]; Niacin inhibits the reaction [IL1B protein results in increased expression of ICAM1 protein]
Niacin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of IL6 mRNA]; Niacin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of IL6 protein] [Curcumin co-treated with Niacin co-treated with ZM 241385] inhibits the reaction [Rotenone results in increased expression of IL6 protein]; Niacin inhibits the reaction [Rotenone results in increased expression of IL6 protein] [Ubiquinone co-treated with Niacin co-treated with Riboflavin] promotes the reaction [Tamoxifen results in decreased expression of IL6 protein]
LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of BTC mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of CIDEA mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of DDHD1 mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of NET1 mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of PCK1 mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of TTPA mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of UCP1 mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of ASPH mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of CASQ1 mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of EDNRB mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of ENO3 mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of GPI1 mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of NRAP mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of PI16 mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of RALGAPA1 mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of SRL mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of TLN1 mRNA]; LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in increased expression of TPM1 mRNA]
[Niacin binds to and results in increased activity of HCAR2 protein] which results in increased phosphorylation of MAPK1 protein; [Niacin binds to and results in increased activity of HCAR3 protein] which results in increased phosphorylation of MAPK1 protein; Pertussis Toxin inhibits the reaction [Niacin results in increased phosphorylation of MAPK1 protein]
[Niacin binds to and results in increased activity of HCAR2 protein] which results in increased phosphorylation of MAPK3 protein; [Niacin binds to and results in increased activity of HCAR3 protein] which results in increased phosphorylation of MAPK3 protein; Pertussis Toxin inhibits the reaction [Niacin results in increased phosphorylation of MAPK3 protein]
Niacin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in decreased expression of NFKBIA protein]; Niacin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased phosphorylation of NFKBIA protein]
Niacin results in increased expression of NOS3 mRNA Niacin results in increased phosphorylation of NOS3 protein [Niacin co-treated with Chromium] inhibits the reaction [CAV1 protein binds to NOS3 protein]; [Niacin co-treated with Chromium] results in increased phosphorylation of NOS3 protein
Niacin results in increased expression of NR1H3 mRNA PPARG protein promotes the reaction [Niacin results in increased expression of NR1H3 mRNA] 2-chloro-5-nitrobenzanilide inhibits the reaction [Niacin results in increased expression of NR1H3 mRNA]; PPARG protein promotes the reaction [Niacin results in increased expression of NR1H3 mRNA]
[Niacin co-treated with Chromium] inhibits the reaction [Dietary Fats results in increased expression of OLR1 mRNA]; [Niacin co-treated with Chromium] inhibits the reaction [Dietary Fats results in increased expression of OLR1 protein]
[Niacin co-treated with Ubiquinone co-treated with Riboflavin] results in increased expression of PARP1 protein Niacin deficiency affects the reaction [Etoposide results in increased cleavage of PARP1 protein]
Niacin results in decreased expression of PCK1 mRNA LEPR gene mutant form promotes the reaction [[Niacin binds to Chromium] which results in decreased expression of PCK1 mRNA]
4-benzhydryloxy-1-(3-(1H-tetrazol-5-yl-)-propyl)piperidine inhibits the reaction [Niacin results in increased activity of PPARG protein]; Aspirin inhibits the reaction [Niacin results in increased activity of PPARG protein]; HCAR2 protein promotes the reaction [Niacin results in increased expression of and results in increased activity of PPARG protein]; HCAR3 protein promotes the reaction [Niacin results in increased activity of PPARG protein]; Niacin results in increased expression of and results in increased activity of PPARG protein; PPARG protein promotes the reaction [Niacin results in increased expression of NR1H3 mRNA]; PTGDS protein promotes the reaction [Niacin results in increased activity of PPARG protein]; PTGS1 protein promotes the reaction [Niacin results in increased activity of PPARG protein] Niacin results in increased expression of PPARG mRNA [Niacin results in decreased abundance of Dinoprost] which results in increased expression of PPARG mRNA; [Niacin results in decreased abundance of Dinoprost] which results in increased expression of PPARG protein; fluprostenol inhibits the reaction [Niacin results in increased expression of PPARG mRNA]; PPARG protein promotes the reaction [Niacin promotes the reaction [APOA1 protein results in increased export of Cholesterol]]; PPARG protein promotes the reaction [Niacin results in increased expression of ABCA1 mRNA]; PPARG protein promotes the reaction [Niacin results in increased expression of NR1H3 mRNA]
PTGS1 protein promotes the reaction [Niacin results in increased activity of PPARG protein] Niacin results in decreased expression of PTGS1 protein PTGS1 protein results in increased susceptibility to Niacin
[Niacin inhibits the reaction [CEBPB protein binds to PTGS2 promoter]] which results in decreased expression of PTGS2 mRNA; [Niacin results in decreased expression of PTGS2 mRNA] which results in decreased abundance of Dinoprost; Niacin inhibits the reaction [CEBPB protein binds to PTGS2 promoter] Niacin results in decreased expression of PTGS2 mRNA; Niacin results in decreased expression of PTGS2 protein
Niacin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of and results in increased activity of RELA protein] Niacin inhibits the reaction [TNF protein results in increased activity of RELA protein] Niacin results in decreased expression of RELA protein
Aspirin inhibits the reaction [Niacin results in increased expression of SCARB1 mRNA]; Niacin promotes the reaction [SCARB1 protein results in increased export of Cholesterol, HDL]; Ro 31-8220 inhibits the reaction [Niacin results in increased expression of SCARB1 mRNA] Niacin results in decreased expression of SCARB1 protein
Niacin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 protein] Niacin results in decreased expression of SERPINE1 protein
[Niacin co-treated with Chromium] promotes the reaction [SLC2A4 protein binds to CAV3 protein]; [Niacin co-treated with Chromium] results in increased localization of SLC2A4 protein
[Curcumin co-treated with Niacin co-treated with ZM 241385] inhibits the reaction [Rotenone results in increased expression of SNCA protein]; Niacin inhibits the reaction [Rotenone results in increased expression of SNCA protein]
[[Niacin co-treated with Chromium] results in increased expression of STAR protein] which results in increased export of Cholesterol; [Niacin co-treated with Chromium] results in increased expression of STAR protein
Niacin inhibits the reaction [Silicon Dioxide results in increased expression of TGFB1 mRNA]; Niacin inhibits the reaction [Silicon Dioxide results in increased expression of TGFB1 protein]; Niacin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 protein] Niacin results in decreased expression of TGFB1 protein
[Ubiquinone co-treated with Niacin co-treated with Riboflavin] promotes the reaction [Tamoxifen results in decreased expression of TNF protein]; Niacin inhibits the reaction [TNF protein results in increased activity of RELA protein]; Niacin inhibits the reaction [TNF protein results in increased expression of CCL2 protein]; Niacin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; Niacin inhibits the reaction [TNF protein results in increased expression of PECAM1 protein]; Niacin inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA] Niacin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF mRNA]; Niacin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein]
Niacin deficiency affects the expression of TP53 protein Niacin deficiency results in decreased expression of TP53 mRNA Niacin deficiency inhibits the reaction [Etoposide results in increased expression of TP53 protein]
Picloram results in decreased expression of FOXO1 mRNA arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide promotes the reaction [Picloram results in decreased expression of FOXO1 mRNA]
Picloram results in decreased expression of GRIN1 mRNA arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide promotes the reaction [Picloram results in decreased expression of GRIN1 mRNA]
Picloram results in decreased expression of COX1 mRNA arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide promotes the reaction [Picloram results in decreased expression of COX1 mRNA]
Picloram results in decreased expression of PRDX5 mRNA arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide inhibits the reaction [Picloram results in decreased expression of PRDX5 mRNA]
ferrous sulfate inhibits the reaction [picolinic acid inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; picolinic acid inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
picolinic acid promotes the reaction [INS1 protein results in decreased expression of UBC mRNA]; picolinic acid promotes the reaction [INS1 protein results in increased expression of IGF1 mRNA]; picolinic acid promotes the reaction [INS1 protein results in increased expression of IGF1R mRNA]
picolinic acid inhibits the reaction [Cisplatin results in increased expression of TNF protein]; picolinic acid inhibits the reaction [Streptozocin results in increased secretion of TNF protein]
picolinic acid promotes the reaction [INS1 protein results in decreased expression of UBC mRNA] picolinic acid results in decreased expression of UBC mRNA
browse the term
